ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial

INTRODUCTION: The unfavourable influence of morphine on the pharmacokinetics of ticagrelor resulting in weaker and retarded antiplatelet effect in patients with acute coronary syndrome (ACS) has been previously shown. Replacing morphine with methoxyflurane, a potent, non-opioid analgesic agent, that...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubica, Aldona, Kosobucka, Agata, Niezgoda, Piotr, Adamski, Piotr, Buszko, Katarzyna, Lesiak, Maciej, Wojakowski, Wojciech, Gasior, Mariusz, Gorący, Jarosław, Kleinrok, Andrzej, Nadolny, Klaudiusz, Navarese, Eliano, Kubica, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098993/
https://www.ncbi.nlm.nih.gov/pubmed/33649058
http://dx.doi.org/10.1136/bmjopen-2020-043330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098993/
https://www.ncbi.nlm.nih.gov/pubmed/33649058
http://dx.doi.org/10.1136/bmjopen-2020-043330

Ejemplares similares